← Back to Home

Phase III Data Released for Personalized mRNA Melanoma Vaccine: Risk of Recurrence or Death Reduced by 42%

From meeting the trial endpoint to clarifying the magnitude of benefit, detailed results for intismeran combined with immunotherapy fill in a key piece of the picture: two-year recurrence-free survival improved by 12.2 percentage points, but whether the treatment extends life still requires longer follow-up.

By SURL BioNews

After melanoma is surgically removed, the next treatment challenge is reducing the chance that the cancer will return. Merck and Moderna have released detailed Phase III results for the personalized mRNA cancer vaccine intismeran autogene: adding the vaccine to postoperative immunotherapy further reduced patients’ risk of recurrence or death, providing quantifiable clinical benefits for this treatment tailored to the characteristics of each tumor.

The two companies announced in August that the trial had succeeded; the data released in October showed the magnitude of the difference. INTerpath-001 enrolled 1,137 patients with stage IIB to IV melanoma whose tumors had been completely removed. The randomized, double-blind trial compared postoperative adjuvant treatment with intismeran plus pembrolizumab against placebo plus pembrolizumab.

According to Merck’s announcement, after a median follow-up of 24.6 months, the combination reduced the risk of recurrence or death by 42% compared with the control group, with a hazard ratio of 0.58 and a 95% confidence interval of 0.45 to 0.75, reaching statistical significance. Two-year recurrence-free survival rates were 82.2% and 70.0%, respectively, a difference of 12.2 percentage points. The 42% figure describes the relative reduction in risk for the composite endpoint during follow-up; it cannot be directly interpreted as a 42% reduction in mortality.

The risk of distant metastasis or death also fell by 38%, but overall survival data remain immature, and follow-up will continue. In other words, current evidence supports the combination’s ability to reduce or delay recurrence and distant metastasis, but does not yet establish that patients live longer; the results also cannot be directly applied to other cancer types or different treatment settings.

The vaccine’s design begins with mutations in each patient’s tumor. Moderna explains that researchers analyze tumor and normal blood samples, then select up to 34 neoantigens predicted to be recognizable by the immune system and encode them in mRNA. The aim is to guide T cells to recognize cancer cells; pembrolizumab, given alongside the vaccine, blocks the inhibitory PD-1 signal to help T cells sustain their antitumor activity.

The difference in efficacy also varied over time. A prespecified sensitivity analysis summarized by Moderna showed that the two groups had similar risks of recurrence or death during the first six months; after six months, the relative risk in the combination group was reduced by 58%. This finding offers a clue about how the treatment effect changes over time, but cannot replace the primary analysis covering all randomized patients, nor is it sufficient on its own to establish the biological reason for the emergence of the difference.

Regarding safety, grade 3 to 5 treatment-related adverse events occurred in 14.2% of the combination group and 13.4% of the control group; common reactions in the combination group included fever, injection-site pain, and fatigue. The two companies said no new safety signals were observed, but this does not mean the treatment is without risk. As the magnitude of benefit becomes clearer, longer-term survival follow-up and regulatory review are still needed to clarify the role of this personalized treatment in postoperative care.

References

  1. pharma.economictimes.indiatimes
  2. Merck
  3. Moderna